Allogene Therapeutics, Inc. (ALLO) SEC Filing 10-Q Quarterly report for the period ending Sunday, March 31, 2019

Allogene Therapeutics, Inc.

CIK: 1737287 Ticker: ALLO
LOGO    Exhibit 99.1

Allogene Therapeutics Reports First Quarter 2019 Financial Results



Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)



Investigational New Drug (IND) Application Submitted to the U.S. Food & Drug Administration (FDA) for ALLO-715 Targeting BCMA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma



Ended First Quarter 2019 with $681 Million in Cash, Cash Equivalents and Investments



Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET

South San Francisco, Calif., May 7, 2019 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T

) therapies for cancer, today provided a corporate update and reported financial results for the quarter ended March 31, 2019.

“We are very pleased with our ability to accelerate the research and development activities for both ALLO-501 and ALLO-715,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “Our focus from day one has been on the acceleration of AlloCAR T therapy to enable an “off-the-shelf” CAR T therapy for patients. In May 2018, we started Allogene with approximately 40 employees. Today, we have over 150 employees, all dedicated to making AlloCAR T therapy a reality.”

Recent Highlights

ALLO-501 (anti-CD19 AlloCAR T)



The ALLO-501 Phase 1 ALPHA trial for patients with relapsed/refractory non-Hodgkin lymphoma (NHL) has been initiated. The trial is designed to assess the safety and tolerability at increasing dose levels of ALLO-501 in the most common NHL subtypes of relapsed/refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Multiple sites with expertise in CAR T are fully activated and the Company continues to expect to report initial data from the trial in the first half of 2020.



The Company is rapidly progressing the planned second generation of ALLO-501 through preclinical development. The second generation ALLO-501 is devoid of the rituximab off-switch and is expected to be introduced prior to the start of the Phase 2 portion of the ALPHA study.

ALLO-715 (anti-BCMA AlloCAR T)



An Investigational New Drug (IND) application has been submitted to the U.S. Food & Drug Administration (FDA) for ALLO-715, a wholly-owned CAR T product candidate targeting B cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma. The Company remains on track to initiate a Phase 1 trial in 2019.

The following information was filed by Allogene Therapeutics, Inc. (ALLO) on Tuesday, May 7, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Allogene Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allogene Therapeutics, Inc..


Assess how Allogene Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Allogene Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheets
Condensed Balance Sheets (Parenthetical)
Condensed Statement Of Cash Flows
Condensed Statement Of Stockholders' Equity (Deficit)
Condensed Statements Of Operations And Comprehensive Loss
Balance Sheets Components
Balance Sheets Components (Tables)
Balance Sheets Components - Schedule Of Accrued Liabilities (Details)
Balance Sheets Components - Schedule Of Prepaid And Other Current Assets (Details)
Balance Sheets Components - Schedule Of Property And Equipment (Details)
Description Of Business
Description Of Business - Additional Information (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Additional Information (Details)
Financial Instruments - Summary Of Cash Equivalents, Restricted Cash And Investments, Classified As Available-For-Sale Securities (Details)
Income Taxes
Leases (Tables)
Leases - Additional Information (Details)
Leases - Summary Of Undiscounted Future Lease Payments Under Lease Liability (Details)
License Agreements
License Agreements - Additional Information (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Schedule Of Anti-Dilutive Shares Excluded From Calculation Of Diluted Net Loss Per Share (Details)
Related Party Transactions
Related Party Transactions - Additional Information (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Schedule Of Restricted Stock Units Activity Under Plan (Details)
Stock-Based Compensation - Schedule Of Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Summary Of Stock Option Activity Under Plan (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Allogene Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ALLO
CIK: 1737287
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-19-016480
Submitted to the SEC: Tue May 07 2019 4:01:49 PM EST
Accepted by the SEC: Tue May 07 2019
Period: Sunday, March 31, 2019
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: